IL318404A - Novel acc inhibitors - Google Patents

Novel acc inhibitors

Info

Publication number
IL318404A
IL318404A IL318404A IL31840425A IL318404A IL 318404 A IL318404 A IL 318404A IL 318404 A IL318404 A IL 318404A IL 31840425 A IL31840425 A IL 31840425A IL 318404 A IL318404 A IL 318404A
Authority
IL
Israel
Prior art keywords
acc inhibitors
novel
novel acc
inhibitors
acc
Prior art date
Application number
IL318404A
Other languages
Hebrew (he)
Inventor
Scott William Bagley
Andrea Nicole Bootsma
Chulho Choi
Robert Lee Dow
David James Edmonds
Carmen Noemi Garcia-Irizarry
Brian Stephen Gerstenberger
Gajendra Ingle
Jessica Gloria Katherine O’Brien
Mihir Dineshkumar Parikh
Gwenaella Christine Rescourio
Daniel Copley Schmitt
Original Assignee
Pfizer
Scott William Bagley
Andrea Nicole Bootsma
Chulho Choi
Robert Lee Dow
David James Edmonds
Garcia Irizarry Carmen Noemi
Brian Stephen Gerstenberger
Gajendra Ingle
Jessica Gloria Katherine O’Brien
Mihir Dineshkumar Parikh
Gwenaella Christine Rescourio
Daniel Copley Schmitt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Scott William Bagley, Andrea Nicole Bootsma, Chulho Choi, Robert Lee Dow, David James Edmonds, Garcia Irizarry Carmen Noemi, Brian Stephen Gerstenberger, Gajendra Ingle, Jessica Gloria Katherine O’Brien, Mihir Dineshkumar Parikh, Gwenaella Christine Rescourio, Daniel Copley Schmitt filed Critical Pfizer
Publication of IL318404A publication Critical patent/IL318404A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
IL318404A 2022-07-29 2023-07-26 Novel acc inhibitors IL318404A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263393712P 2022-07-29 2022-07-29
PCT/IB2023/057576 WO2024023727A1 (en) 2022-07-29 2023-07-26 Novel acc inhibitors

Publications (1)

Publication Number Publication Date
IL318404A true IL318404A (en) 2025-03-01

Family

ID=87571535

Family Applications (1)

Application Number Title Priority Date Filing Date
IL318404A IL318404A (en) 2022-07-29 2023-07-26 Novel acc inhibitors

Country Status (19)

Country Link
US (1) US12655157B2 (en)
EP (1) EP4562017B1 (en)
JP (1) JP7734874B2 (en)
KR (1) KR20250037569A (en)
CN (1) CN120019059A (en)
AR (1) AR130069A1 (en)
AU (1) AU2023316863A1 (en)
CA (1) CA3263179A1 (en)
CL (1) CL2025000240A1 (en)
CO (1) CO2025000972A2 (en)
CR (1) CR20250035A (en)
DK (1) DK4562017T3 (en)
DO (1) DOP2025000009A (en)
IL (1) IL318404A (en)
MA (1) MA71611A (en)
MX (1) MX2025001176A (en)
PY (1) PY2359799A (en)
TW (1) TWI860797B (en)
WO (1) WO2024023727A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025133948A1 (en) * 2023-12-21 2025-06-26 Pfizer Inc. Acetyl coa-carboxylase (acc) inhibitors
CN119876334B (en) * 2025-03-21 2025-06-24 北京索莱宝科技有限公司 Enzyme activity determination method, kit and application of acetyl-CoA carboxylase

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (en) 1990-01-23 1999-01-15 . Cyclodextrin derivatives with increased water solubility and uses thereof
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
PE20081559A1 (en) * 2007-01-12 2008-11-20 Merck & Co Inc SPIROCHROMANONE DERIVATIVES SUBSTITUTED AS ACETYL COA CARBOXYLASE INHIBITORS
EP2123652A1 (en) 2007-02-20 2009-11-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
AU2008223348A1 (en) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
JP5435592B2 (en) 2008-05-28 2014-03-05 ファイザー・インク Pyrazolospiroketone acetyl CoA carboxylase inhibitor
UA102336C2 (en) * 2009-11-10 2013-06-25 Пфайзер Інк. N1-PYRAZOLSPIRACETONS AS ACETYL-COA-CARBOXYLASE INHIBITORS
CN103189377B (en) * 2010-10-29 2015-02-25 辉瑞大药厂 N1/n2-lactam acetyl-coa carboxylase inhibitors
IN2014MN02652A (en) 2012-06-08 2015-08-21 Gilead Sciences Inc
MX2016002479A (en) 2013-09-12 2016-05-31 Pfizer Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris.
CN116003321A (en) 2018-05-09 2023-04-25 北京加科思新药研发有限公司 Novel heterocyclic derivatives useful as SHP2 inhibitors
AU2019385438A1 (en) 2018-11-20 2021-05-27 The National Institutes of Pharmaceutical R&D Co., Ltd. Spiro compound and medical uses thereof
WO2021026672A1 (en) 2019-08-09 2021-02-18 Novartis Ag Heterocyclic wdr5 inhibitors as anti-cancer compounds

Also Published As

Publication number Publication date
EP4562017A1 (en) 2025-06-04
KR20250037569A (en) 2025-03-17
TW202415668A (en) 2024-04-16
EP4562017B1 (en) 2026-07-01
US12655157B2 (en) 2026-06-16
PY2359799A (en) 2024-02-02
CL2025000240A1 (en) 2025-05-09
MX2025001176A (en) 2025-03-07
CO2025000972A2 (en) 2025-02-13
CA3263179A1 (en) 2024-02-01
AR130069A1 (en) 2024-10-30
DOP2025000009A (en) 2025-04-08
TWI860797B (en) 2024-11-01
DK4562017T3 (en) 2026-07-20
JP7734874B2 (en) 2025-09-05
US20240109915A1 (en) 2024-04-04
WO2024023727A1 (en) 2024-02-01
CR20250035A (en) 2025-03-18
AU2023316863A1 (en) 2025-02-13
JP2025524984A (en) 2025-08-01
MA71611A (en) 2025-05-30
CN120019059A (en) 2025-05-16

Similar Documents

Publication Publication Date Title
EP4262807A4 (en) Azaquinazoline pan-kras inhibitors
IL325340A (en) Kras inhibitors
EP3982949A4 (en) MRSA1 INHIBITORS
IL326137A (en) Pi3k inhibitors
IL314049A (en) Parp7 inhibitors
IL310394A (en) Inhibitors for coronaviruses
IL321625A (en) Malt1 inhibitors
IL317105A (en) Novel par-2 inhibitors
IL325676A (en) Kat6 inhibitor
IL327069A (en) Myst inhibitors
IL291611A (en) Jak inhibitors
IL315980A (en) Egfr inhibitors
EP4025564A4 (en) NITRIFICATION INHIBITORS
EP3965760A4 (en) Synthesis of crac channel inhibitors
GB202209916D0 (en) Aco inhibitors
EP4263533C0 (en) Erap inhibitors
IL320219A (en) Inhibitors
GB202311032D0 (en) Acc
CA3280616A1 (en) Novel alpk1 inhibitors
CA3299341A1 (en) Parp7 inhibitors
HK40130936A (en) Vanin-1 inhibitors
CA3286215A1 (en) Vanin-1 inhibitors
CA3279779A1 (en) Prmt5-mta inhibitors
HK40128988A (en) Inhibitors
AU2021900853A0 (en) Novel inhibitors